Phase I/II multicenter, randomized, open-label trial of the c-Met inhibitor MSC2156119J and gefitinib versus chemotherapy as second-line treatment in patients with MET-positive (MET plus ), locally advanced, or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor mutation (EGFRm plus ) and progression on gefitinib

被引：0
|
作者：
Wu, Yi-Long
Yang, James Chih-Hsin
Park, Keunchil
Xu, Lianzhe
Bladt, Friedhelm
Johne, Andreas
Li, Peiqi
Zheng, Hongxia
Massimini, Giorgio
机构：
[1] GGH, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Innovat Canc Med Inst, Seoul, South Korea
[5] Merck Serono Pharmaceut R&D Co Ltd, Global Biostat, Beijing, Peoples R China
[6] Merck KGaA, Translat Innovat Platform Oncol, Global Res & Dev, Darmstadt, Germany
[7] Merck KGaA, Clin Pharmacol, Darmstadt, Germany
[8] Merck Serono Pharmaceut R&D Co Ltd, Global Clin Dev Ctr, Beijing, Peoples R China
[9] EMD Serono, Global Res & Early Dev, Boston, MA USA
[10] Merck KGaA, Global Res & Early Dev, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps8121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8121
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of tepotinib plus gefitinib (TEP plus GEF) in MET-positive (MET plus )/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)
    Cheng, Y.
    Zhou, J.
    Lu, S.
    Zhang, Y.
    Zhao, J.
    Pan, H.
    Chen, Y-M.
    Chian, C-F.
    Bruns, R.
    Johne, A.
    Scheele, J.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2018, 29 : 493 - 493
  • [2] A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET plus ) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.
    Gin, Shukui
    Cheng, Ann-Lii
    Lim, Ho Yeong
    Xu, Lianzhe
    Biadt, Friedhelm
    Johne, Andreas
    Li, Cindy
    Zheng, Hongxia
    Massimini, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] ORAL C-MET INHIBITOR MSC2156119J AS MONOTHERAPY VERSUS SORAFENIB IN FIRST-LINE TREATMENT OF ASIAN PATIENTS WITH MET-POSITIVE ADVANCED HEPATOCELLULAR CARCINOMA AND CHILD-PUGH CLASS A LIVER FUNCTION: PHASE IB/II, MULTICENTER, RANDOMIZED TRIAL
    Ann-Lii, Cheng
    Yeong, Lim Ho
    Xu Lianzhe
    Cindy, Li
    Giorgio, Massimini
    Qin Shukui
    ANNALS OF ONCOLOGY, 2014, 25 : 74 - 74
  • [4] Management of patients with epidermal growth factor receptor mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC) after radiological progression to first-line therapy with gefitinib.
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFRmutated non-small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
    Chen, Likun
    Hou, Xue
    Li, Meichen
    Wu, Guowu
    Feng, Weineng
    Su, Jin
    Jiang, Honghua
    Jiang, Guanming
    Zhang, Baishen
    Chen, Jing
    You, Zhixuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
    Mok, Tony
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Rosell, Rafael
    Jaime, Jesus Corral
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf Gerhard
    Sbar, Eric
    Wang, Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC).
    Spigel, David R.
    Edelman, Martin J.
    Mok, Tony
    O'Byrne, Kenneth John
    Paz-Ares, Luis
    Yu, Wei
    Rittweger, Karen
    Thurm, Holger C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.
    Mok, Tony
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Rosell, Rafael
    Jaime, Jesus Corral
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf Gerhard
    Sbar, Eric
    Wang, Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [10] Phase I study of gefitinib (G) plus durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations
    Creelan, B. C.
    Yeh, T.
    Kim, S-W.
    Nogami, N.
    Kim, D-W.
    Chow, L. Q.
    Kanda, S.
    Taylor, R.
    Tang, W.
    Tang, M.
    Angell, H. K.
    Roudier, M. P.
    Marotti, M.
    Gibbons, D. L.
    ANNALS OF ONCOLOGY, 2019, 30
12345